Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark's Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].
According to IQVIA® sales data for the 12-month period ending June 2026, the Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL) market2 achieved annual sales of approximately $69.9 million
The products are bioequivalent and therapeutically equivalent to the reference drug marketed by Fresenius Kabi.
According to IQVIA data, the combined US market for Calcium Gluconate Injection for all these strengths was worth approximately $69.9 million in the 12 months ended June 2026.
Calcium gluconate injection is primarily used for the treatment of acute symptomatic hypocalcemia.
Marc Kikuchi, president & business head, North America, said: 'The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark’s U.S. injectables business and expanding our hospital portfolio.
It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business – one that addresses institutional needs, supports greater supply resilience and deepens Glenmark’s relevance across the U.S. healthcare system.”
Glenmark Pharmaceuticals manufactures pharmaceutical formulations and active pharmaceutical ingredients, which it markets in India and abroad. It also undertakes R&D on new chemical and biological entities. The company has 10 manufacturing facilities spread across India, USA and a few other countries.
The company's consolidated net profit surged 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Revenue rose by 28.52% to Rs 3,931.73 crore in Q1 FY27 over Q1 FY26.
The scrip shed 0.54% to currently trade at Rs 2312.35 on the BSE.
Glenmark Pharmaceuticals (Glenmark) today announced the receipt of U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray.
Glenmark's Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase®2 Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121] and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIA® sales data for the 12-month period ending June 2026, the Flonase® Nasal Spray market achieved annual sales of approximately $295.2 million.
With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 2307, up 0.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Glenmark Pharmaceuticals Ltd has risen around 6.97% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 2.35 lakh shares today, compared to the daily average of 5.85 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2315.7, up 0.36% on the day. Glenmark Pharmaceuticals Ltd is up 4.64% in last one year as compared to a 4.17% drop in NIFTY and a 15.39% drop in the Nifty Pharma index.
The PE of the stock is 40.66 based on TTM earnings ending March 26.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa®2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].
According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million.
According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.
The company reported a 6,381.9% increase in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26, compared with Q4 FY25.